Doctorate at CEA, France
Professional Profiles
Google Scholar
Scopus
Orcid
🎓 Educational Background
Dr. Aloïse Mabondzo, has a distinguished academic foundation. He earned his Master’s degree in Molecular and Cellular Biology from the University of Strasbourg, France (1986-1989). Driven by a passion for cutting-edge research, he pursued a PhD in Virology and Immunology at the prestigious Pierre and Marie Curie University, France (1989-1993). His doctoral work focused on Active Immunotherapy using bispecific antibodies against HIV, a testament to his early commitment to tackling global health challenges.
🧪 Professional Positions
Dr. Mabondzo’s illustrious career began with a Post-doctoral Research Fellowship (1993-1997) at the CEA Neurovirology Department, where he made significant contributions to the field of neurovirology. In 1998, he joined the CEA Medicine and Healthcare Technologies Department, where he has served as Research Director and Head of the Neurovascular Unit Research and Therapeutic Innovation Laboratory. His leadership in these roles has driven breakthroughs in neurovascular research. Since 2019, Dr. Mabondzo has also been the Co-founder and Research Director of Ceres Brain Therapeutics, a startup dedicated to pioneering therapeutic innovations.
👩🏫 Mentoring and Supervision
Dr. Mabondzo has a proven track record as a mentor and supervisor. Over his career, he has supervised 16 PhD candidates (10 past, 6 current), 7 Postdoctoral Fellows (4 past, 3 current), and several other researchers, including 2 Research Assistants, 2 Engineers, and 2 Technicians. His mentorship has nurtured the next generation of scientists, fostering innovation and collaboration.
Publications Top Noted📄
Dodecyl creatine ester therapy: from promise to reality
Authors: Mabondzo, A.; van de Kamp, J.; Mercimek-Andrews, S.
Journal: Cellular and Molecular Life Sciences
Year: 2024
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Authors: Angeli, E.; Paris, J.; Le Tilly, O.; Paintaud, G.; Bousquet, G.
Journal: Experimental Hematology and Oncology
Year: 2024
Impaired brain glucose metabolism as a biomarker for evaluation of dodecyl creatine ester in creatine transporter deficiency: Insights from patient brain-derived organoids and in vivo [18F]FDG PET imaging in a mouse model
Authors: Disdier, C.; Soyer, A.; Broca-Brisson, L.; Tournier, N.; Mabondzo, A.
Journal: Neurobiology of Disease
Year: 2024
Targeting the Multiple Complex Processes of Hypoxia-Ischemia to Achieve Neuroprotection
Authors: Maïza, A.; Hamoudi, R.; Mabondzo, A.
Journal: International Journal of Molecular Sciences
Year: 2024
Epigenetic alterations in creatine transporter deficiency: a new marker for dodecyl creatine ester therapeutic efficacy monitoring
Authors: Broca-Brisson, L.; Disdier, C.; Harati, R.; Hamoudi, R.; Mabondzo, A.
Journal: Frontiers in Neuroscience
Year: 2024